Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients

Inclusion Criteria: * Each patient must meet all of the following inclusion criteria to be enrolled in the study: * Patient is of a legally consenting age as defined by local regulations. * Patient is, in the investigator(s) opinion willing and able to comply with the protocol requirements. * Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. * Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * Male patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study. * Patient was previously diagnosed with multiple myeloma based on standard criteria (see Section 13.2). * Patient is relapsed after one line of treatment but less than three lines, including high-dose chemotherapy with stem cell support, conventional poli-chemotherapy, thalidomide- and melphalan-based regimens * Patient with primary refractory disease will be considered not eligible * Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, greater than 1 g/dL of IgG M-Protein and greater than 0.5 g/dL of IgA M-Protein) and, where applicable, urine light-chain excretion of \>200 mg/24 hours. * Patient has a Karnofsky performance status ≥60%. * Patient has a life-expectancy \>3 months. * Patient has the following laboratory values within 14 days before Baseline (day 1 of the Cycle 1, before study drug administration): * Platelet count ≥90 x 109/L without transfusion support within 7 days before the test. * Absolute neutrophil count (ANC) ≥ 1.00 x 109/L without the use of growth factors * Corrected serum calcium ≤14 mg/dL (3.5 mmol/L). * Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal (ULN). * Alanine transaminase (AST): ≤ 2.5 x the ULN. * Total bilirubin: ≤ 1.5 x the ULN. * Calculated or measured creatinine clearance: ≥20 mL/minute Exclusion Criteria: Patients meeting any of the following exclusion criteria are not to be enrolled in the study. * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. * Pregnant or beast feeding females. * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Use of any other concomitant standard/experimental anti-myeloma drug or therapy * Known positive for HIV or active infectious hepatitis, type B or C * Other concurrent anticoagulation treatment